Although “cancer” is talked about as if it were a single disease, it is an umbrella concept covering numerous different diseases that share a common biological logic. Frequently heard cancer types such as breast, lung, colon, prostate or thyroid meet in the idea of “uncontrolled multiplication”. Despite this, they can differ markedly in terms of where they start from, how they behave, at what speed they can progress and which biological weak points they carry.
In this article, we address, within a general framework, the basic common features that cancer types share and why they differ, without distorting the logic behind clinical decisions. The content is for general information purposes and does not replace a medical assessment.
The Basic Mechanisms That Make Cancer Types Common
The most basic common feature of cancer is that the cells partially or completely stretch the rules they should normally comply with. In healthy tissue, cell division is kept in balance through mechanisms such as damage control, immune surveillance and harmony with the surrounding tissue. In cancer, on the other hand, the cell can, with the accumulation of genetic and epigenetic changes, turn this balance in its own favour.
One dimension of this commonality is the disruption of the control of growth signals. Cancer cells can become more sensitive to growth signals or can produce their own growth signal. This situation is, in some tumours, associated with disruptions occurring in the intracellular communication networks. In clinical practice, an approach such as “the same pathway is disrupted in every patient” is not correct; biomarkers and pathology findings help to understand which mechanism may be more prominent.
Another common mechanism is the tendency to avoid cell death. A normal cell, when it takes serious damage, prevents bigger problems by destroying itself. A cancer cell, on the other hand, can disable these “brake” systems. In this way, a damaged cell line can over time gain an advantage and continue to multiply.
As the tumour grows, its need for nutrients and oxygen increases. For this reason, in many cancer types, processes that increase blood vessel formation can come into play. Saying that this occurs “in the same way in every cancer” is not correct; the microenvironment of the tumour, the tissue it is in and its biology affect this picture markedly.
One of the most critical common headings from a clinical standpoint is the potential for spread to surrounding tissues and metastasis. Saying that every cancer metastasises is not correct. However, in many cancer types, the risk of progression to the surrounding tissue and attachment to distant organs over time can come into consideration. How much this risk is and how it is monitored varies according to the type and subtype of the cancer.
Why Is Cancer Not a Single Type?
The first and strongest reason for the differentiation between cancer types is the tissue the disease originates from. Because each tissue runs different genes, responds to different hormones and has a different immune microenvironment. For this reason, the same idea of “uncontrolled multiplication” can turn into completely different clinical pictures between skin cancer and a brain tumour, or between lymphoma and colon cancer.
For example, in diseases of blood and lymphatic system origin, the concept of a “mass” may not always be at the forefront. Blood values, the bone marrow and the immune system can play a more visible role. In contrast, in digestive system cancers, mechanisms such as the tumour’s behaviour in the bowel wall, obstruction or bleeding can become more determining. In thyroid cancer, on the other hand, the clinical course can progress on a slow or more aggressive line according to the subtype.
That is, “where the cancer starts” is not just a label. It is the basic layer that affects the symptom, the monitoring, the staging approach and the treatment planning manner.
There Can Be More Than One Cancer in the Same Organ
The second major layer that differentiates cancer types is that there can be more than one subtype even in the same organ. “Breast cancer” is not a single disease. Some features reflecting the hormone receptors, the HER2 status and the cellular multiplication speed can affect the approach. In lung cancer, too, main distinctions such as small cell and non-small cell, and then molecular subgroups, can come into consideration.
At this point, the concepts of genetic tests, molecular profiling and biomarkers come into play. The aim is to understand the biological characteristics of the tumour better. Despite this, a generalisation such as “every test is carried out in every patient” is not correct. Which test will be meaningful varies according to the cancer type, the stage and the clinical question.
Why Are the Spread Patterns Different?
Although the word metastasis is the same, the story is not the same in every cancer. Some cancers may be more inclined to progress through the lymphatic route, some through the blood route and some along neighbouring tissues. These tendencies can turn into patterns talked about more frequently in some cancers in clinical practice. For example, intra-abdominal surfaces in ovarian cancer, bone involvement in prostate cancer or liver-related spread patterns in colon cancer can come into consideration more.
The point that needs to be paid attention to here is this: These do not mean “it definitely happens this way”. They are only patterns that can be seen more frequently in clinical practice. Still, these patterns can affect many decisions, from the imaging plan to the follow-up strategy. For this reason, staging and risk assessment cannot be reduced to a single symptom or a single test result.
Why Do the Treatment Approaches Change?
In cancer treatment, the goal can change according to the stage and biological characteristics of the disease. While in some scenarios the aim of bringing the disease fully under control is more prominent, in some scenarios managing the disease for a long time and protecting the quality of life can come to the fore. For this reason, surgery, radiotherapy, systemic treatments and some targeted approaches can be planned with different combinations according to the cancer type and subtype.
While some cancer types or subgroups can follow a course more sensitive to certain treatments, in some types the tumour biology and microenvironment can make the treatment response more difficult. At this point, the pathology findings, the stage, the biomarkers, the accompanying diseases and the person’s priorities are evaluated together. For this reason, making an inference such as “a single treatment gives the same result in every patient” is not correct.
The Risk Factors Can Be Common, but Their Effects Are Not the Same
Headings such as smoking, obesity, physical inactivity, some infections, sun and UV exposure and genetic predisposition can be associated with many cancer types. However, the weight of these factors in each cancer type is not the same. While, when lung cancer is mentioned, smoking is talked about as a more dominant risk heading, in cervical cancer the HPV association or in skin cancer UV exposure can come to the fore more prominently.
For this reason, risk discussions are generally person-specific. Making inferences such as definitely happens or definitely does not happen over a single factor is not sound.
Frequently Asked Questions
What Is the Common Point of Cancer Types?
The basic commonality is the disruption of the cellular control mechanisms and the tendency of damaged cells to gain an advantage over time and multiply. However, this common core does not look the same in every cancer.
Why Can Cancer in the Same Organ Behave Differently?
There can be different cell origins and different biological subtypes in the same organ. Layers such as hormone receptors, genetic changes and the tumour microenvironment can affect the behaviour.
Does Metastasis Definitely Occur in Every Cancer?
No. The risk of metastasis varies according to the type, subtype and stage of the cancer. While some cancers can follow a more limited course, some can carry a higher spread potential.
Are Biomarker and Genetic Tests Necessary in Every Patient?
Saying that the same tests are necessary in every patient is not correct. Which test will be meaningful is determined according to the type and stage of the cancer and the clinical question.
Does This Content Replace Diagnosis or Treatment?
No. This text is for general information purposes. For a personal risk, diagnosis and follow-up plan, the assessment of health professionals is essential.
Through the informative content on our site, you can expand the general framework about cancer types, staging and the place of biomarkers in the clinical decision processes, and you can convey your questions within the scope of general information through the contact channels. This content does not replace a medical assessment.
